Iron Leaf Capital Corp IRON 深 滬
已收盤 12-24 16:00:00 美东时间
80.43
+0.610
+0.76%
華盛通- 最 高80.73
- 今 開80.00
- 成交量 16.84万股
- 最 低 79.31
- 昨 收 79.82
- 總市值 30.36亿
- 52周最高 99.50
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 30.82
- 委 比 -29.99%
- 總股本 3775.02万
- 歷史最高 190.85
- 量 比 0.13
- 振 幅 1.78%
- 歷史最低 11.60
- 每 手 1
- 風險率 14.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
12-17 10:46
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $109
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $91 to $109.
12-16 22:56
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Disc Medicine'sPhase 2 RALLY-MF trial shows DISC-0974 reduces hepcidin and improves iron levels, leading to significant anemia responses. 63% of nTD patients saw ≥1 g/dL hemoglobin increase持续12周, while 71% of TD Low patients achieved transfusion independence. DISC-0974 was well-tolerated, with diarrhea and UTIs as leading mild AEs. The drug demonstrated efficacy across patient subgroups, including those on JAK inhibitors. Disc aims to advance the...
12-06 13:00
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $114
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $86 to $114.
11-11 00:24
Disc Medicine Q3 EPS $(1.77) Misses $(1.51) Estimate
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.51) by 16.91 percent. This is a 98.88 percent decrease over losses of $(0.89) per share from
11-06 21:40
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, Inc. (NASDAQ:IRON) will participate in fireside chats at three upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on November 10th, Stifel 2025 Healthcare Conference on November 13th, and Jefferies London Healthcare Conference on November 19th. Live webcasts and archived replays will be available on the company's investor relations website. The biopharmaceutical company is focused on developing...
10-31 12:30
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $115.
10-31 02:04
